BeiGene Entered into a Clinical Supply Agreement with Phanes Therapeutics to Evaluate PT199 + Tislelizumab for Multiple Advanced Solid Tumors
Shots:
- The companies collaborated to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of PT199 in the P-I study in combination with BeiGene's tislelizumab for multiple advanced solid tumors that have progressed after all available standard therapy
- Through the activation of Ab-dependent macrophage-mediated killing of T effector cells, binding to Fc receptors on macrophages has been demonstrated in pre-clinical studies of tislelizumab to compromise the anti-tumor activity of PD-1 Ab
- PT199 is an anti-CD73 mAb that inhibits the enzyme activities of both soluble and membrane-bound CD73. Tislelizumab is being studied in solid tumors and hematologic malignancies as monotx. and in combination
Ref: PRNewswire | Image: BeiGene
Click here to read the full press release